Summit Awarded Additional $12 Million by BARDA for Ridinilazole
(WorldNews Health)

Summit Therapeutics plc (`Summit` or `the Company`) Summit Awarded Additional $12 Million by BARDA for Phase 3 Development Programme of Ridinilazole for the Treatment of C. difficile Infection o Brings Total Committed Funding Under BARDA Contract to $44 Million Oxford, UK, and Cambridge, MA, US, 16 August 2018 - Summit Therapeutics plc (NASDAQ:SMMT, AIM:SUMM), a leader in antibiotic innovation, today announces that it has been awarded an additional $12 million under its contract with the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response. The funds will...